Emmaus Life Sciences Reports Quarterly Financial ResultsSeptember 10, 2024
Emmaus Life Sciences, Inc., today reported on its financial condition and results of operations as of and for the year quarters ended March 31 and June 30, 2024.
Read More
Emmaus Life Sciences, Inc., today reported on its financial condition and results of operations as of and for the year quarters ended March 31 and June 30, 2024.
Read MoreEmmaus Life Sciences, Inc., announced that Willis C. Lee has been appointed as Chief Executive Officer.
Read MoreEmmaus Life Sciences, Inc., today announced receiving the coveted "No Action Indicated" classification following a routine inspection by the United States Food and Drug Administration (FDA) of Emmaus' Postmarketing Adverse Drug Experience (PADE) compliance program.
Read MoreEmmaus Life Sciences, Inc., today reported on its financial condition and results of operations as of and for the year ended December 31, 2023.
Read MoreEmmaus reported today that the filing of its Annual Report on Form 10-K for the year ended December 31, 2023 will be delayed.
Read More